$0.7015
-0.03-3.89%
At close: -
$0.7099
0.008401.20%
After Hours: 7:59 PM EDT
Comments
Loading...
ImmunoPrecise Antibodies Earnings Estimates, EPS & Revenue | NASDAQ:IPA | Benzinga
ImmunoPrecise Antibodies reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Jul 28
EPS Estimate
$-0.050
Quarterly Revenue Estimate
$5.02M
Annual Revenue
(as of Jan 31)
(as of Jan 31)
$24.00M
Analyze the earnings history of ImmunoPrecise Antibodies using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPA | ImmunoPrecise Antibodies | -$0.58 | -$0.05 | — | — | $4.72M | $5.02M | — | — | 07/28/2025 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.08 | -$0.06 | -$0.01 | 76.67% | $4.55M | $4.93M | $4.33M | -12.17% | 03/28/2025 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.07 | -$0.05 | -$0.07 | -40.00% | $4.62M | $5.11M | $4.49M | -12.21% | 12/10/2024 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.14 | -$0.08 | -$0.11 | -37.50% | $4.26M | $4.96M | $3.87M | -21.96% | 09/16/2024 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.15 | -$0.08 | -$0.58 | -625.00% | $4.15M | $4.72M | $4.72M | 0.02% | 07/29/2024 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.14 | -$0.07 | -$0.08 | -14.29% | $3.84M | $4.50M | $4.55M | 1.22% | 03/14/2024 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.23 | -$0.10 | -$0.07 | 26.00% | $3.90M | $4.33M | $4.62M | 6.74% | 12/14/2023 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.30 | -$0.15 | -$0.10 | 33.33% | $3.65M | $3.94M | $4.26M | 8.17% | 09/14/2023 | Get Alert |
| IPA | ImmunoPrecise Antibodies | $0.17 | -$0.13 | -$0.15 | -15.38% | $4.11M | $4.23M | $4.15M | -1.87% | 07/07/2023 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.16 | -$0.17 | -$0.14 | 17.65% | $3.80M | $3.96M | $3.84M | -3.11% | 03/16/2023 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.21 | — | -$0.23 | — | $3.76M | $3.84M | $3.90M | 1.51% | 12/15/2022 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.14 | — | -$0.30 | — | $3.73M | $4.02M | $3.65M | -9.33% | 09/14/2022 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.29 | — | $0.17 | — | $4.88M | $4.48M | $4.11M | -8.37% | 07/29/2022 | Get Alert |
| IPA | ImmunoPrecise Antibodies | — | -$0.13 | -$0.16 | -23.08% | — | $4.14M | $3.80M | -8.16% | 03/16/2022 | Get Alert |
| IPA | ImmunoPrecise Antibodies | — | — | -$0.21 | — | — | — | $3.76M | — | 12/13/2021 | Get Alert |
| IPA | ImmunoPrecise Antibodies | — | — | -$0.14 | — | — | — | $3.73M | — | 09/09/2021 | Get Alert |
| IPA | ImmunoPrecise Antibodies | -$0.01 | — | -$0.29 | — | $4.15M | — | $4.88M | — | 07/28/2021 | Get Alert |
ImmunoPrecise Antibodies (IPA) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2025-03-28 | $-0.01 | $-0.06 | 76.7 % |
| Q2 | 2024-12-10 | $-0.07 | $-0.05 | -40.0 % |
| Q1 | 2024-09-16 | $-0.11 | $-0.08 | -37.5 % |
| Q4 | 2024-07-29 | $-0.58 | $-0.08 | -625.0 % |
ImmunoPrecise Antibodies (IPA) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | 2025-03-28 | $4.33M | $4.93M | -12.2 % |
| Q2 | 2024-12-10 | $4.49M | $5.11M | -12.2 % |
| Q1 | 2024-09-16 | $3.87M | $4.96M | -22.0 % |
| Q4 | 2024-07-29 | $4.72M | $4.72M | 0.02 % |
FAQ
When is ImmunoPrecise Antibodies (NASDAQ:IPA) reporting earnings?
ImmunoPrecise Antibodies (IPA) is scheduled to report earnings on July 28, 2025. The last reported earnings were for reported on March 28, 2025 for Q3.
What were the latest earnings per share (EPS) for ImmunoPrecise Antibodies (NASDAQ:IPA)?
The Actual EPS was $-0.01, which beat the estimate of $-0.06.
What were ImmunoPrecise Antibodies’s (NASDAQ:IPA) revenues?
The Actual Revenue was $4.3M, which missed the estimate of $4.9M.
Browse earnings estimates, EPS, and revenue on all stocks.
